Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
The regulator says at-home ultrasounds and heart monitoring systems are a bad idea.
Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.
The regulator is allowing generic makers room on the OTC contraceptive shelf.
Pfizer's consumer website for Advil in South Korea offers a strange appeal to women who experience menstrual pain.
The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.
Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.
The drugmaker may be able to settle around 3,800 cases for $100 million.
The White House has until Friday to issue a response to a Supreme Court injunction that temporarily eased birth-control coverage requirements.
A Penn State researcher thinks it can help women with menstrual cramps.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The AAP says greater access and education are critical in curbing STIs.
Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.
The diagnostics firm is undercutting Myriad's cost by almost $1,000.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.
The second-line drug sped from Priority Review status for the first-line indication to approval in just over two months.
Researchers surveying 21 Long Island mammography centers found that women do not know their risk.
The drug maker brought together a group of five established healthcare advocates under the umbrella GLAM, short for Great Life After Menopause. The advocates will keep their distinct voices, which are anything but muted.
The drug maker's broadcast-heavy "OAB reality" campaign stresses the emotional toll on women.
J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
The CDC says HPV vaccination rates are not improving. The latest data comes just as a recent report shows the vaccine cannot only help fend off cervical cancer, but throat cancers as well.
The first prescription non-hormonal treatment offers relief for women who do not want to tangle with hormone-replacement therapy.
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director's Q&A
The first drug for morning sickness in thirty years enters the market this month.
Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
The regulator tells manufacturers to halve the recommended doses of zolpidem sleep-aids. Purdue Pharma's Intermezzo already hits the mark, but the drugmaker doesn't anticipate a sales jump or new messaging strategy.